MGA’s Alex Brill Serves as a Panelist at the National Coalition on Health Care’s Capitol Hill Forum
From the Coalition to Protect Patient Choice:
“The last panelist was Alex Brill… [who] spoke about FDA reform and specifically about patent issues relating to biologic drugs and their generic counterparts known as biosimilars. He stated that biosimilar entry has not been as robust as was envisioned by the Affordable Care Act, due to archaic regulatory schemes, anticompetitive conduct, and cost-benefit analysis.”
